The Institute of Cancer Research at FoG London 2027
Jan 27–28, 2027 London, UK ~8.3k attendees Website
The Institute of Cancer Research takes part in 6 sessions at FoG London 2027 in London, its home city. Its sessions cover cancer risk prediction and testing, plus spatial biology and circulating tumour DNA for tracking tumours. Concrete topics include prostate cancer polygenic risk from the BARCODE1 study, multiplex assays to resolve variants of uncertain significance, and direct-to-patient genetic testing for the NHS.
| Organization | FoG London 2027 Attendance |
|---|---|
The Institute of Cancer Research London, UK | |
Cancer research institute and college of the University of London, working in partnership with The Royal Marsden. | Talk Wed Jan 27 12:30–13:00 Direct-to-Patient (DTP) Genetic Testing Pathways: Unlocking Capacity For The NHS Genomic Medicine Service and Genomic Population Health Service How offering genetic tests directly to patients could widen access while easing pressure on NHS genomic services. Talk Wed Jan 27 12:30–13:00 Polygenic Risk Scores for Prostate Cancer Risk Stratification - Lessons From the BARCODE1 Study How polygenic risk scores, which add up many small genetic effects, could better target prostate cancer screening and weigh the risk of overdiagnosis. Talk Wed Jan 27 14:30–15:00 MAVEs: Multiplex Assays of Functional Effect: Saying Goodbye To VUSs? How lab assays measuring the effects of thousands of genetic variants at once could settle uncertain variants in cancer genetic testing. Talk Wed Jan 27 14:30–15:00 Mapping the Invasive Tumour: How Spatial Biology is Revealing Cancer's Next Move How spatial biology, which maps cells where they sit in tissue, shows how tumour layout and support cells help cancer invade. Talk Wed Jan 27 15:30–16:00 Exploiting Genome Evolution in Inflammatory Bowel Disease to Prevent Colorectal Cancer How cells with abnormal chromosome numbers spread through the inflamed colon years before visible change, flagging future cancer risk in inflammatory bowel disease. Talk Thu Jan 28 11:30–12:00 Integrating Circulating Tumour DNA into Treating Head and Neck Cancer How testing tumour DNA in the blood can guide head and neck cancer treatment, both curative and palliative, and what challenges remain. |
Find decision makers at The Institute of Cancer Research
Tell us what you sell and we’ll find the people at The Institute of Cancer Research most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by Front Line Genomics or the Festival of Genomics. Submit a correction